Will the Catholic Church & the U.S. Courts Embrace Advanced Cell Technologies “Embryo-Safe” Technique Using Embryonic Stem Cells?
Released on: May 10, 2011, 5:41 am
Author:
investorstemcell.com
Industry: Financial, Biotech, Healthcare
Advanced Cell Technology with laboratory facilities in Marlborough Massachusetts has
pioneered a solution to the ethical, moral & legal debate raging in regards to
protection of a human embryo. ACT has developed the “single-blastomere” technique.
Patent Number 7,893,315 a non-destructive alternative for deriving human embryonic
stem cell (hESC) lines.
This achievement in Regenerative medicine is a ground breaking feat for both
Catholic and U.S. law.
• The 1995 encyclical The Gospel of Life, of which Pope John Paul II wrote: "Human
embryos obtained in vitro are human beings and are subjects with rights; their
dignity and right to life must be respected from the first moment of their
existence. It is immoral to produce human embryos destined to be exploited as
disposable 'biological material'" (1,5 )
• The Dickey Amendment (also known as the Dickey-Wicker Amendment) is the name of an
appropriation bill rider attached to a bill passed by United States Congress in
1995, and signed by former President Bill Clinton, which prohibits the Department of
Health and Human Services (HHS) from using appropriated funds for the creation of
human embryos for research purposes or for research in which human embryos are
destroyed.
The single-blastomere technology uses a one-cell biopsy approach similar to
pre-implantation genetic diagnosis (PGD), which is widely used in the in vitro
fertilization (IVF) process and does not interfere with the embryo’s developmental
potential. The stem cells generated using this approach are healthy, completely
normal, and differentiate into all the cell types of the human The safety record
for one-cell biopsy as part of PGD now has a 15-year track record, and is carried
out routinely as part of IVF processes around the world. ACT’s technique of
protecting the human embryo from harm can be expounded to the smallest blood
transfusion in the world. As does a human being give millions of blood cells in a
pint of blood so does ACT’s “single blastomere” process take but “one cell” from a 2
day old embryo. As the blood removed from a human donor “regenerate” the removed
pint of blood so does the human embryo “regenerate” the one cell. Both of these
procedures leave the human body & two day old embryo healthy. Both procedures are
similar in that they both provide life saving material to those whom need them most
to due to disease and other aliments of a medical nature.
Advanced Cell Technology has been granted by the US Food and Drug Administration
(FDA) a Phase I/II multicenter clinical trial using retinal cells derived from
human embryonic stem cells for both Stargardt’s Macular Dystrophy (SMD), one of the
most common forms of juvenile macular degeneration in the world and Dry Age-Related
Macular Degeneration (AMD) the most common form of macular degeneration in the world
affecting an estimated 150 million people. ACT is using RPE cells developed from
the patented (SCB) technique for this trial. The trial will take place at UCLA’s
Jules Stein Eye Institute in California. Because of the biological nature of the
human eye the trial will be able to provide a 100% irrefutable proof that the (hESC)
derived RPE cells used attached to the Bruch’s membrane. Before and after state of
the art imaging will take place.
Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the
world’s foremost experts in retinal cell physiology and vision restoration,
commented, “The study results of ACT’s RPE cells implanted in the various animal
models of macular degeneration was phenomenal. If ACT observes even a fraction of
that benefit in humans, it will be nothing short of a home run."
FDA validation will occur for (hESC) medicine in less than 12 months. Will those
that dictate law and morality to others lead? Will those suffering from disease all
over the world finally have conclusive proof that (hESC) work? Life is filled with
multifaceted choices and in a rare occurrence a quantum leap shows itself to the
world. Human flight, computers and now regenerative medicine.
Disclosure: Stem Cell Media LLC nor its Companies was compensated by “any” entity
for this article. www.investorstemcell.com is bringing investors and stakeholders
together to participate in the world’s only online discussion forum dedicated to
regenerative medicine.
Contact Details: icell@investorstemcell.com
www.investorstemcell.com
Back to previous page
Home page
Submit your press release